Recent Developments in Drug Design of Oral Synthetic Free Fatty Acid Receptor 1 Agonists
Lei Liu, Qinghua Zhang, Yichuan Ma, Ling Lin, Wenli Liu, Aizhong Ding, Chunjian Wang, Shuiping Zhou, Jinyong Cai, Hai Tang · 2024
Read Recent Developments in Drug Design of Oral Synthetic Free Fatty Acid Receptor 1 Agonists by Lei Liu, Qinghua Zhang, Yichuan Ma, Ling Lin, Wenli Liu, Aizhong Ding, Chunjian Wang, Shuiping Zhou, Jinyong Cai, Hai Tang (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11646431.txt.
Description
Lei Liu and nine co-authors review twenty years of work on a class of diabetes drug candidates that keep stalling at the liver, in this 2024 review. These compounds switch on the FFAR1 receptor to coax insulin out. Several reached large trials, yet none has won approval, mostly because they injured the liver.
The review traces the harm to the molecules' greasy acid heads, which spawn toxic byproducts. Newer designs shrink the molecule, cut the grease, and borrow shapes from natural products. One candidate built that way looks liver-safe so far and sits in mid-stage trials. The authors also survey hopes beyond diabetes, in fatty liver and stroke, and point to AI-aided design as the way forward.
Catalog record
| CREATOR | Lei Liu, Qinghua Zhang, Yichuan Ma, Ling Lin, Wenli Liu, Aizhong Ding, Chunjian Wang, Shuiping Zhou, Jinyong Cai, Hai Tang |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 41 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |